Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366030 | 0.95 | KMT2A (0.41) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3685958 | 0.93 | MEN1 (0.36) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL13338188 | 0.93 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL13338199 | 0.92 | TDP1 (0.40) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL29468020 | 0.91 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL366334 | 0.91 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL2977544 | 0.91 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL2977784 | 0.90 | MEN1 (0.36) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3579943 | 0.90 | KMT2A (0.40) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3418938 | 0.90 | KMT2A (0.36) | KMT2AMEN1HPGDNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | claimed |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-14 | — | — | US | claimed |
| EP-1669353-B1 | Process for preparing alpha, beta - unsaturated esters | DAISO CO LTD (JP) | 2009-05-20 | — | — | EP | claimed |
| EP-1791905-B1 | MIXTURE, POLYESTER COMPOSITION, FILM AND METHOD FOR PRODUCING THE SAME | LURGI ZIMMER GMBH (DE) | 2008-12-03 | — | — | EP | claimed |
| EP-1791905-A1 | MIXTURE, POLYESTER COMPOSITION, FILM AND METHOD FOR PRODUCING THE SAME | Zimmer AG (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | claimed |
| CN-1902159-A | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LTD (NZ) | 2007-01-24 | — | — | CN | claimed |
| WO-2006034745-A1 | MIXTURE, POLYESTER COMPOSITION, FILM AND METHOD FOR PRODUCING THE SAME | ZIMMER AG (DE) | 2006-04-06 | — | — | WO | claimed |
| EP-1264852-B1 | Process for the preparation of polyester resins | MONTEFIBRE SPA (IT) | 2004-07-28 | — | — | EP | claimed |
| EP-1572113-B1 | CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9447100-B2 | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20140155416-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| CN-1902159-B | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LTD | 2010-06-09 | — | — | CN | disclosed |
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
| EP-0320753-A2 | Derivatives of cyclic aminoacids, their preparation, compounds containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-06-21 | — | — | EP | disclosed |
| EP-0301401-A2 | Leukotriene antagonists, process for their preparation, their use in the treatment of illnesses | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-01 | — | — | EP | disclosed |
| EP-0080154-B1 | N-SUBSTITUTED 2-PYRIDYL INDOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL USE | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | disclosed |
| EP-0129051-A2 | Substituted indoles | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
| EP-0126401-A1 | Indole compounds | CIBA-GEIGY AG (CH) | 1984-11-28 | — | — | EP | disclosed |
| EP-0080154-A2 | N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use | CIBA-GEIGY AG (CH) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | HRH2, HRH4, H1-2 | KMT2A 75/4885MEN1 2521/4885HPGD 1510/4885 |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, PNP | KMT2A 1372/4885MEN1 3896/4885HPGD 109/4885 |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, QDPR | KMT2A 1079/4885MEN1 3811/4885HPGD 111/4885 |
| US-20140155416-A1 | SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS | CASR, NR2C2, RYR1 | KMT2A 3123/4885MEN1 3119/4885HPGD 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.